Inflammatory Versus Degenerative Joint Disease: How to Tell Them Apart and Why the Treatment Differs

Two people have painful, stiff hands. The same symptom, described in almost the same words.

One has mechanical wear in the joints. Her treatment is exercise, weight, load management and something for the pain, and nothing bad happens if she takes a few weeks to get organised.

The other has an immune system attacking her joint lining. Her treatment is a drug that suppresses that process, started within weeks, and every month of delay costs joint tissue that does not come back.

Giving the second woman an anti-inflammatory and sending her away is the most consequential mistake in this entire subject. She will feel better. The erosion will continue.

🔎 The distinction, feature by feature

Almost all of this is available from the history, before any test. The most useful single question is about the morning.

Two lines in that table do most of the work. Stiffness over an hour and better with movement, worse with rest together point firmly at inflammation, and either one on its own is worth an appointment.

📋 Which conditions sit where

• 🔥 Inflammatory: rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis and ankylosing spondylitis, lupus, polymyalgia rheumatica, gout and other crystal disease
• ⚙️ Degenerative: osteoarthritis of knee, hip, hand and spine; disc and facet degeneration; most tendon problems
• 🔄 Both at once, commonly: someone can have osteoarthritis in the knees and rheumatoid arthritis in the hands. And long-standing inflammatory disease produces secondary degenerative change in the joints it has damaged, so a person can have inflammatory-type pain and wear-type pain in the same body

The overlap goes the other way too, which is worth knowing because it causes confusion. Osteoarthritis is not purely mechanical — there is real inflammation in the joint lining during flares, which is why anti-inflammatories work better than paracetamol for it. That does not make it an immune disease and does not change the treatment.

Two patterns are worth naming because they get mislabelled. Pain around a joint on specific movements, with the joint itself not swollen, is usually tendon and soft tissue — see our guide to periarthritis. And a single hot, red, exquisitely painful joint coming on over hours is crystal disease or infection, and it is covered in our guide to joint pain along with the emergency features.

⏳ Why the twelve weeks matter

This is the practical consequence of getting the distinction right.

In immune-driven arthritis there is a window of opportunity: treatment started within roughly the first twelve weeks of symptoms produces substantially better long-term joint outcomes than the same treatment started a year later. Damage done during the delay does not reverse.

So the cost of mislabelling inflammatory disease as wear and tear is not a few uncomfortable months. It is permanent. And the mislabelling is easy, because an anti-inflammatory works on both — the patient feels better, everyone concludes the diagnosis was right, and the erosion proceeds quietly.

What this means for anyone reading with the inflammatory pattern: ask for blood tests and a rheumatology referral, not a stronger painkiller. The tests are inflammatory markers, rheumatoid factor and anti-CCP antibodies, and the useful phrasing is: my stiffness lasts over an hour in the mornings and improves when I move, both hands are affected the same way, and I would like this assessed for inflammatory arthritis.

What treatment then looks like is set out in our guides to rheumatoid arthritis and methotrexate and, where more is needed, moderate to severe disease.

🏋️ What actually changes degenerative disease

Here the good news is real and the best treatment is not a tablet.

And three things to stop spending on: glucosamine and chondroitin, which large trials have not separated from placebo; collagen drinks, which are digested like any other protein; and copper or magnetic bands. Reassurance worth having: clicking and crunching in a joint, without pain, is normal and does not mean damage.

💊 Meloxicam, with the real numbers

Mobic (Meloxicam) is an anti-inflammatory that preferentially blocks the enzyme involved in inflammation over the one protecting the stomach lining, which gives it a somewhat better gastrointestinal profile than older agents.

Two honest points about what it is and is not:

• ✅ Its real advantages: once-daily dosing, and a gentler stomach profile than ibuprofen or diclofenac at equivalent effect
• ❌ What it is not: a stronger painkiller than the alternatives. Anti-inflammatories are broadly comparable for pain at equivalent doses, and claims that one is dramatically superior do not survive examination

The alternatives, each with a reason to pick it: naproxen for one of the more favourable cardiovascular profiles; celecoxib or etoricoxib where stomach risk is the main concern; ibuprofen for short courses; and a topical gel for a surface joint, which is the lowest-risk option of all.

⚠️ Anti-inflammatory safety, stated properly

These are genuinely useful drugs with genuinely real risks, and the risks scale with age, dose and duration rather than appearing out of nowhere.

• 🩸 Stomach and bowel. Ulceration and bleeding, often without warning pain. Risk rises with age over 65, previous ulcer, higher doses, and concurrent steroids, blood thinners or SSRI antidepressants. A stomach-protecting tablet should be prescribed alongside where any of those apply
• 🚰 Kidneys. The combination that causes most harm is an anti-inflammatory plus an ACE inhibitor or ARB plus a diuretic, particularly during a dehydrating illness. If you are on blood pressure medication and develop vomiting or diarrhoea, stop the anti-inflammatory and take advice
• ❤️ Heart and blood pressure. They raise blood pressure, cause fluid retention, can destabilise heart failure, and at high doses over long periods carry a cardiovascular risk. Relevant in inflammatory arthritis, which already raises that risk — see our guides to blood pressure and cholesterol
• 🚫 Never two at once, including a tablet with a gel
• 💊 Interactions to raise: lithium, blood thinners, and methotrexate — which matters because people with inflammatory arthritis take both, and the combination needs attention to kidney function
• 🫁 Avoid entirely if an anti-inflammatory or aspirin has ever worsened your asthma or caused nasal polyps and wheeze
• 🤰 Avoid in late pregnancy, and discuss earlier pregnancy first

Monitoring for anything beyond a short course: blood pressure, kidney function and a blood count. That is what regular review actually means.

💊 What treats the inflammatory half

Briefly, so the contrast is concrete. These drugs suppress the immune process rather than the symptom, and they are the reason outcomes in inflammatory arthritis have changed so much in a generation.

• 🔹 Methotrexate — the anchor drug, taken once a week, never daily, with folic acid on a separate day
• 🔹 Leflunomide and sulfasalazine — alternatives and combination partners
• 🔹 Baricitinib and the biologics — where conventional treatment is not enough
• 🔹 Prednisolone — a short bridge while the above take effect, not a destination
• 🔹 Allopurinol for gout, which is the one inflammatory condition with a removable cause: lower the uric acid below target and the attacks stop

All of these require diagnosis, dosing and monitoring from a clinician. The point of listing them here is only to make the contrast visible: if your pattern is the inflammatory one, this is the column your treatment should be in, and an anti-inflammatory belongs alongside it rather than instead of it.

🚬 What applies to both

Four things help whichever column you are in.

• 🚭 Stopping smoking. It helps cause inflammatory arthritis, worsens it, and reduces how well the medication works. It also lowers the cardiovascular risk that both conditions carry. The highest-value single change — see our guide to smoking cessation
• 🏃 Movement. Exercise does not damage inflamed or worn joints. The old advice to rest them was wrong in both conditions
• ⚖️ Weight. It loads degenerative joints mechanically and reduces the chance of reaching remission in inflammatory disease
• 😴 Sleep. Poor sleep measurably amplifies pain, and pain wrecks sleep. Breaking that loop reduces reported pain independently of any drug

Diet deserves one honest sentence: a Mediterranean pattern has modest supportive evidence in inflammatory disease and none that approaches the effect of medication. No diet treats either condition.

📞 When to seek help

Within a week or two:

• Morning stiffness lasting over an hour, especially with symmetrical swelling of the small joints of the hands or feet — this is the twelve-week window
• Joint pain that improves with movement and worsens with rest, at any age
• Night pain in the second half of the night that eases on getting up
• Joint symptoms with fatigue, unexplained weight loss or low-grade fever
• Soft, warm, puffy swelling rather than bony enlargement
• Psoriasis, nail pitting, a painful red eye, or bowel symptoms alongside joint pain
• New joint pain over 50 with shoulder and hip girdle stiffness, which has its own diagnosis and responds dramatically once identified

Worth an appointment:

• Needing an anti-inflammatory most days for more than a couple of weeks — a reason to reassess rather than to continue
• No improvement in function after a few months of exercise and weight measures in degenerative disease
• Repeated gout attacks — ask about lowering uric acid rather than treating each attack
• Over 65, ulcer history, kidney disease, heart failure, or on blood thinners or blood pressure medication — before starting any anti-inflammatory
• On methotrexate and considering an anti-inflammatory
• Sleep or daily function genuinely lost, which is the point at which surgical options are discussed in degenerative disease

❓ Frequently asked questions

📑 Sources and editorial

• Rheumatology society guidelines distinguishing inflammatory from non-inflammatory joint disease, and referral criteria for suspected inflammatory arthritis
• Evidence on the window of opportunity in early inflammatory arthritis and the effect of treatment initiated within the first weeks to months on long-term joint outcomes
• Osteoarthritis management guidelines, including the place of exercise, weight reduction and topical anti-inflammatories, and the absence of structure-modifying effect from analgesics
• Randomised trials of exercise and muscle strengthening in knee osteoarthritis, including comparison with pharmacological analgesia
• Biomechanical studies of knee joint loading relative to body weight, and trials of weight reduction in symptomatic knee osteoarthritis
• Evidence that non-steroidal anti-inflammatory drugs do not modify structural progression in osteoarthritis or prevent erosion in rheumatoid arthritis
• Comparative effectiveness and tolerability data across non-steroidal anti-inflammatory drugs, including the lack of clinically important differences in analgesic efficacy at equivalent doses
• Prescribing information for meloxicam, including the 7.5 mg starting dose, the 15 mg daily maximum, dosing in older adults and duration guidance
• Guidance on the gastrointestinal, renal and cardiovascular risks of non-steroidal anti-inflammatory drugs, indications for gastroprotection, and the combined renal risk of an anti-inflammatory with renin-angiotensin blockade and a diuretic
• Literature on interactions between non-steroidal anti-inflammatory drugs and methotrexate, lithium and anticoagulants, and on aspirin-exacerbated respiratory disease
• Guidance on disease-modifying therapy in rheumatoid arthritis, on glucocorticoid bridging, and on urate-lowering therapy targets in gout
• Literature on synovial inflammation in osteoarthritis and on secondary degenerative change following inflammatory joint damage
• Randomised trials of glucosamine and chondroitin in osteoarthritis, and reviews of oral collagen supplementation
• Evidence on smoking as a causal and prognostic factor in inflammatory arthritis, and on cardiovascular risk in inflammatory joint disease
• Related reading: joint pain and which treatment reaches which joint, rheumatoid arthritis and methotrexate, moderate to severe rheumatoid arthritis, periarthritis, lower back pain
• Related products: Mobic (Meloxicam), Arcoxia (Etoricoxib), Celebrex (Celecoxib), Jonac (Diclofenac Gel), Methotrexate, arthritis category, pain medicine category
• RXshop Editorial Team — reviewed by Emily Chen, MD, MPH — Internal Medicine Specialist